Cargando…
A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence
INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302695/ https://www.ncbi.nlm.nih.gov/pubmed/30636831 http://dx.doi.org/10.4103/ijp.IJP_544_17 |
_version_ | 1783382035311624192 |
---|---|
author | Sharma, Pramod Kumar Misra, Arup Kumar Gupta, Ajay Singh, Surjit Dhamija, Puneet Pareek, Puneet |
author_facet | Sharma, Pramod Kumar Misra, Arup Kumar Gupta, Ajay Singh, Surjit Dhamija, Puneet Pareek, Puneet |
author_sort | Sharma, Pramod Kumar |
collection | PubMed |
description | INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved, frequency, severity, and preventability of the ADRs occurred. MATERIALS AND METHODS: Data on ADRs of retrospective cohorts were extracted from the filled ADR forms received from the department of radiation oncology. Descriptive statistic was used to summarize and analyze the available data, namely patient demography, causality, severity, and preventability of the event. RESULTS: A total of 191 chemotherapy-induced ADR reports were received from 164 patients during the period March 2015 to August 2017. Almost three-fourth of the ADRs occurred in patients who were receiving regimens involving multiple drugs. Taxanes, alkylating agents, and platinum compounds were the common drug groups involved. The skin (n = 90) was the most frequently involved organ with alopecia and hyperpigmentation as most common manifestations. The severity (Hartwig and Siegel) and preventability scales (Modified Schumock and Thornton) indicated that most reactions were mild (54.45%) in nature and the majority of them were preventable. More than two-third (69%) of the reactions were related “possible” to the suspected drug as determined by the World Health Organization causality assessment. CONCLUSION: Chemotherapy-related ADRs among cancer patients are worrisome. It has a negative impact on patient quality of life and in addition increases cost of therapy. It is found that timely reporting of chemotherapy-related ADRs and having an effective ADR monitoring system in place ensure preventability of the ADRs in many cases. Oncologists, Radiotherapists and Onco-surgeons should be actively involved in ADR reporting (Onco-Pharmacovigilance) and exchange constructive information, update and educate each other about appropriate use of anticancer drugs. Onco-pharmacovigilance is the need of the hour and could be of immense value in reducing morbidity and mortality if practiced with utmost importance. |
format | Online Article Text |
id | pubmed-6302695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63026952019-01-11 A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence Sharma, Pramod Kumar Misra, Arup Kumar Gupta, Ajay Singh, Surjit Dhamija, Puneet Pareek, Puneet Indian J Pharmacol Research Article INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved, frequency, severity, and preventability of the ADRs occurred. MATERIALS AND METHODS: Data on ADRs of retrospective cohorts were extracted from the filled ADR forms received from the department of radiation oncology. Descriptive statistic was used to summarize and analyze the available data, namely patient demography, causality, severity, and preventability of the event. RESULTS: A total of 191 chemotherapy-induced ADR reports were received from 164 patients during the period March 2015 to August 2017. Almost three-fourth of the ADRs occurred in patients who were receiving regimens involving multiple drugs. Taxanes, alkylating agents, and platinum compounds were the common drug groups involved. The skin (n = 90) was the most frequently involved organ with alopecia and hyperpigmentation as most common manifestations. The severity (Hartwig and Siegel) and preventability scales (Modified Schumock and Thornton) indicated that most reactions were mild (54.45%) in nature and the majority of them were preventable. More than two-third (69%) of the reactions were related “possible” to the suspected drug as determined by the World Health Organization causality assessment. CONCLUSION: Chemotherapy-related ADRs among cancer patients are worrisome. It has a negative impact on patient quality of life and in addition increases cost of therapy. It is found that timely reporting of chemotherapy-related ADRs and having an effective ADR monitoring system in place ensure preventability of the ADRs in many cases. Oncologists, Radiotherapists and Onco-surgeons should be actively involved in ADR reporting (Onco-Pharmacovigilance) and exchange constructive information, update and educate each other about appropriate use of anticancer drugs. Onco-pharmacovigilance is the need of the hour and could be of immense value in reducing morbidity and mortality if practiced with utmost importance. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6302695/ /pubmed/30636831 http://dx.doi.org/10.4103/ijp.IJP_544_17 Text en Copyright: © 2018 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Research Article Sharma, Pramod Kumar Misra, Arup Kumar Gupta, Ajay Singh, Surjit Dhamija, Puneet Pareek, Puneet A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence |
title | A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence |
title_full | A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence |
title_fullStr | A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence |
title_full_unstemmed | A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence |
title_short | A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence |
title_sort | retrospective analysis of reporting of adverse drug reactions to oncology drugs: an experience from a national center of clinical excellence |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302695/ https://www.ncbi.nlm.nih.gov/pubmed/30636831 http://dx.doi.org/10.4103/ijp.IJP_544_17 |
work_keys_str_mv | AT sharmapramodkumar aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT misraarupkumar aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT guptaajay aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT singhsurjit aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT dhamijapuneet aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT pareekpuneet aretrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT sharmapramodkumar retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT misraarupkumar retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT guptaajay retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT singhsurjit retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT dhamijapuneet retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence AT pareekpuneet retrospectiveanalysisofreportingofadversedrugreactionstooncologydrugsanexperiencefromanationalcenterofclinicalexcellence |